Worldwide: No Silver Lining For Biocidal Products Now Under The EU Regulatory Cloud

Last Updated: November 8 2019
Article by Lawrence E. Culleen and Tom Fox

The EU Commission has recently confirmed that certain silver compounds will not be approved for use in biocidal (antimicrobial) products in the EU. This could have implications within and well beyond the EU—including in the US and in markets where various “silver-treated” products are manufactured for world-wide distribution.

Biocidal products are used to protect against harmful organisms such as viruses, bacteria and mold. The EU regulates the placing on the market and use of biocidal products via the EU's Biocidal Products Regulation (EU) 528/2012 (BPR). The BPR applies directly across all EU Member States and restricts the placing on the market of biocides in substances, mixtures and articles.

The determinations follow evaluations undertaken of applications for use of silver copper zeolite, silver sodium hydrogen zirconium phosphate, and silver zeolite. The applications were for use of the substances in certain product types: disinfectants and algaecides not intended for direct application to humans or animals (type 2) and film preservatives (type 7).

The European Chemicals Agency's (ECHA) Biocidal Products Committee initially concluded in October 2018 that the substances should not be approved for use in these product types. Following further consideration of the draft decisions, and representations from the United States, this position has now been confirmed and Commission Implementing Decisions will shortly be published.

Since March 2017, when transitional provisions ran out, articles placed on the EU market, including those imported from outside the EU, may only be treated with biocidal products containing active substances approved in the EU.

Biocidal products are broadly defined as:

"…any substance or mixture, in the form in which it is supplied to the user, consisting of, containing or generating one or more active substances, with the intention of destroying, deterring, rendering harmless, preventing the action of, or otherwise exerting a controlling effect on, any harmful organism by any means other than mere physical or mechanical action, — any substance or mixture, generated from substances or mixtures which do not themselves fall under the first indent, to be used with the intention of destroying, deterring, rendering harmless, preventing the action of, or otherwise exerting a controlling effect on, any harmful organism by any means other than mere physical or mechanical action. A treated article that has a primary biocidal function shall be considered a biocidal product". (Article 3(1)(a) BPR).

"Treated article" means:

"…any substance, mixture or article which has been treated with, or intentionally incorporates, one or more biocidal products". (Article 3(1)(l) BPR).

A treated article may, depending upon claims made for it, itself fall within the definition of a biocidal product. However, the BPR also contains provisions which apply to treated articles which are themselves not biocidal products. Such treated articles may not be placed on the market in the EU unless all active substances contained in the biocidal products that it was treated with or incorporates are approved for use in the EU for the specific product type.

It has been argued that the EU's decisions in relation to these silver compounds, introduced a new threshold of requiring "benefit" to be demonstrated and that this was not justified as a technical barrier to trade on public health or environmental grounds. The EU's response has been that ECHA had not introduced any new criteria in making these decisions, it had only applied the standard of "efficacy" in line with the requirements of the BPR. It was the responsibility of the applicant seeking approval for a product use to show that the biocidal product was effective in the manner claimed for it.

The EU position remains that making available on the market a biocidal product which is not sufficiently effective is a public health and environmental health issue. It may unnecessarily expose humans, animals and the environment to biocidal active substance, generate health and/or environmental risks and impacts, and may also contribute to the development of resistance to biocides leading to other health and/or environmental issues. The approach of the EU's BPR is to try and make the use of biocidal products sustainable by limiting their use to the minimum necessary.

It remains open to any applicant to seek approval under the BPR for the particular biocidal uses of these silver compounds. However, sufficient data to demonstrate both safety and efficacy will be required.

These decisions and the factual basis for them could have profound implications for manufacturers not only in the EU but elsewhere, including in the US where there a considerable number of silver compounds already authorized for use in the manufacture of products that contain these forms of silver as an antimicrobial "materials preservative".

In the US, products that incorporate silver as a preservative and which bear claims with regard to the presence of the silver compound as an antimicrobial preservative are subject to US regulation as "pesticides" under US law. When a product claims to control microorganisms (such as bacteria, mould, mildew, fungi) other than on or in humans or animals, the product is considered to be an antimicrobial product, and such products are regulated under the US law concerning pesticides. See generally, the Federal Insecticide, Fungicide and Rodenticides Act (FIFRA), 7 U.S.C. §§136-136y.

Thus, in the US, the form of silver preservative incorporated to such commodities must be registered with the US Environmental Protection Agency for use as a "materials preservative". Moreover, when distributed in the US, the commodities (articles) that are preserved using the silver additives may only be marketed using very modest claims, either claims that are specifically authorized by EPA (if the article itself has been registered by that agency) or a restricted set of claims that may be made for "treated articles" that are exempt from the EPA's pesticide registration requirements. However, to qualify for this exemption, the additive that is incorporated into the treated article must have been registered with EPA and labeled specifically for the purpose of being used as a materials preservative. For such products to remain "exempt" the treated article must not be marketed with claims that the article, or the additive within it, have an antimicrobial effect on anything that is outside of the article itself. (The "treated articles" exemption has been codified within EPA's pesticide regulations at 40 CFR §152.25(a)). If the treated article conforms to the requirements of the regulation and is marketed solely within its limitations, the article is effectively exempt "from all provisions of FIFRA". 40 CFR §152.25.

The ECHA determinations underlying the EU decisions fundamentally call into question the effectiveness of certain silver based compounds as antimicrobials, even as material preservatives. This is likely to raise concerns for makers of products that rely on the same chemistries in the US. Although the US pesticide registration regulations require the makers of antimicrobial products that make claims to control pathogens that are harmful to humans to demonstrate the effectiveness of their disinfectants and sterilants as part of their registration dossier. The makers of materials preservatives generally are not required to submit to EPA data demonstrating the preservative's effectiveness as a condition of registration. It is possible the US EPA might, in light of the ECHA findings, issue a "data call-in" notice in the US seeking to collect existing data on the substances effectiveness. Moreover, Section 6(a)(2) of the US pesticides law has been interpreted by EPA to require the timely submission to EPA of data which show that a "public health" pesticide (e.g., a hospital grade disinfectant or sterilant) is ineffective.

Companies manufacturing or using the affected silver compounds in their products will not only need to reconsider whether they are still permitted to place these on the market in the EU, they will also need to ask themselves in what other jurisdictions such findings might create impediments in the market, or even new affirmative reporting obligations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions